PPD has gained a deal to sell its development and marketing rights to all dipeptidyl peptidase IV inhibitors to Takeda for $15 million up front along with unspecified milestones for any successful product development. PPD gained the rights in an earlier deal with Syrrx. Takeda bought Syrrx in March and renamed it Takeda San Diego.
- read this press release for more